|
|
Anaptysbio Inc (NASDAQ: ANAB) |
|
Price: $17.0800
$-0.49 
-2.789%
|
| Day's High:
| $18.21
| Week Perf:
| 3.45 %
|
| Day's Low: |
$ 16.93 |
30 Day Perf: |
-9.49 % |
| Volume (M): |
1,442 |
52 Wk High: |
$ 41.31 |
| Volume (M$): |
$ 24,624 |
52 Wk Avg: |
$24.86 |
| Open: |
$17.46 |
52 Wk Low: |
$12.21 |
|
|
| Market Capitalization (Millions $) |
484 |
| Shares
Outstanding (Millions) |
28 |
| Employees |
40 |
| Revenues (TTM) (Millions $) |
91 |
| Net Income (TTM) (Millions $) |
-145 |
| Cash Flow (TTM) (Millions $) |
87 |
| Capital Exp. (TTM) (Millions $) |
0 |
Anaptysbio Inc
AnaptysBio Inc. is a biotechnology company that focuses on the discovery and development of antibody therapeutics. The company harnesses the power of its proprietary somatic hypermutation (SHM) platform to generate novel antibodies for various diseases across different therapeutic areas. Through its platform, AnaptysBio can create fully human antibodies with improved binding affinity, specificity, and potency, thereby potentially providing more effective treatments for patients. The company collaborates with pharmaceutical partners to advance its pipeline of antibody candidates, aiming to address unmet medical needs and make a positive impact in the field of biopharmaceuticals.
Company Address: 10770 Wateridge Circle San Diego 92121 CA
Company Phone Number: 362-6295 Stock Exchange / Ticker: NASDAQ ANAB
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Management Announcement
Published Wed, Aug 14 2024 9:00 AM UTC
San Diego-based clinical-stage biotechnology company, Anaptys Biosciences, has recently announced the successful completion of a $100 million underwritten registered direct offering. This landmark transaction was led by long-standing investor EcoR1 Capital, with notable participation from additional existing and new investors, including pharmaceutical giant Sanofi....
|
| Anaptysbio Inc
AnaptysBio Inc: Navigating Growth Amid Financial Challenges
On August 5, 2024, AnaptysBio, Inc. (Nasdaq: ANAB), a San Diego-based clinical-stage biotechnology company, reported compelling financial results for the second quarter ending June 30, 2024. The company's revenue soared by an impressive 217.08% year-over-year, reaching $10.97 million. However, the financial picture was mixed, as AnaptysBio also reported an increased net loss and deficit per share.
Financial Overview
AnaptysBio?s significant revenue increase contrasts sharply with its performance in the previous financial reporting period. The $10.97 million in revenue reflects a dramatic 52.82% surge from $7.18 million in the first quarter of 2024. This growth is particularly noteworthy when compared to the broader Major Pharmaceutical Preparations sector, which saw a modest revenue increase of only 0.01% during the same timeframe.
|
| Anaptysbio Inc
AnaptysBio Inc, a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, recently announced a very robust revenue growth of 422.489% year on year to $7.18 million in the first quarter of 2024. This significant increase in revenue highlights the company's success in the Major Pharmaceutical Preparations industry. In comparison to its sector peers, AnaptysBio outperformed many other companies, with most businesses in the industry reporting a top-line growth of 2.72% in the same period.
However, AnaptysBio did experience an increased loss per share at $-1.64, compared to the preceding quarter where the loss per share was $-1.59. Additionally, revenue fell by -20.278% from $9.01 million in the preceding quarter. Despite this, the company reported a net loss of $-43.936 million in the first quarter of 2024, which was an improvement from the deficit of $-44.255 million in the same quarter a year ago.
|
| Clinical Study
Published Thu, May 9 2024 8:10 PM UTC
AnaptysBio, a clinical-stage biotechnology company, has recently reported positive top-line results from their Phase 3 clinical trials involving the experimental drug imsidolimab (IL-36R mAb). Designed to address the challenges posed by generalized pustular psoriasis (GPP), a severe orphan disease known for its potential life-threatening consequences, these trials evaluated ...
|
| Anaptysbio Inc
AnaptysBio Inc, a major pharmaceutical preparations company, has experienced a slight decline in its share price over the last five trading days. With a decrease of -5.16%, the current share price is now at 14.29% during the first quarter of 2024. However, it is important to note that despite this recent decline, AnaptysBio's shares have been trending upward and are only 9.8% away from reaching its 52-week high.
Looking at the company's recent financial performance, AnaptysBio reported a deficit per share of -$1.59 in the most recent fiscal period. Despite this deficit, the company's revenue saw a significant surge of 32.271%, reaching $9.01 million compared to the same quarter a year prior. In the previous quarter, the company's revenue stood at $3.32 million with a deficit per share of -$1.41.
|
| Per Share |
Current |
| Earnings (TTM) |
-5.15 $ |
| Revenues (TTM) |
3.22 $
|
| Cash Flow (TTM) |
3.07 $ |
| Cash |
13.59 $
|
| Book Value |
2.5 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-5.15 $
|
| Revenues (TTM) |
3.22 $ |
| Cash Flow (TTM) |
3.07 $ |
| Cash |
13.59 $
|
| Book Value |
2.5 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
1.8%